Press Releases

RSS
  • May 31, 2016
    ENGLEWOOD, Colo., May 31, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that its Chief Operating Officer, Jarrett Disbrow, and Managing Director of International Operations, David Yakich, will attend the 2016 Biotechnology Innovation Organization (BIO) Inter...
    May 25, 2016
    ENGLEWOOD, Colo., May 25, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that its shareholders voted to approve a proposal authorizing the Company's Board of Directors to amend Aytu's certificate of incorporation to effect a reverse split of the Company's co...
    May 24, 2016
    ENGLEWOOD, Colo., May 24, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that its Chief Executive Officer, Josh Disbrow, will present at The 2016 Marcum MicroCap Conference being held at the Grand Hyatt New York in New York City. ...
    May 18, 2016
    ENGLEWOOD, Colo., May 18, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today provided an update on the strategic steps it has taken to expand and optimize its commercial infrastructure in support of the planned July 2016 launch of the Company's newest product Natesto® in...
    May 11, 2016
    ENGLEWOOD, Colo., May 11, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended March 31, 2016.  The Company will host a live conference call and webcast today a...
    May 10, 2016
    ENGLEWOOD, Colo., May 10, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical findings that further validate and expand the potential utility of its MiOXSYS System as an advanced tool for assessing oxidative stress in human semen, which is broadly im...
    May 6, 2016
    ENGLEWOOD, Colo., May 6, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced the closing of its previously announced underwritten public offering of 18,750,000 shares of its common stock and warrants to purchase up to an aggregate of 20,799,250 shares of its common stock at ...
    May 5, 2016
    ENGLEWOOD, Colo., May 5, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, announced today that the Company will present its operational results for the third fiscal quarter of 2016 on Wednesday, May 11, 2016, at 4:30 p.m. ET.  The Company will review recent accomplishments a...
    May 2, 2016
    ENGLEWOOD, Colo., May 2, 2016 /PRNewswire/ -- Aytu BioScience, Inc. ("Aytu") (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology, today announced that it has priced an underwritten public offering of 18,750,000 shares of its common stock and warrants to purchase up to an aggregate of 18,750,000 shares of its common stock at a combine...
    Apr 25, 2016
    ENGLEWOOD, Colo., April 25, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on commercializing novel products in the field of urology today announced the exclusive licensing of its third commercial-stage urology product in just 11 months, with the execution of a long-term, exclusive license agreement with an affiliate of Acerus Pharmaceuticals ...